ContraFect Corporation (CFRX) Sets 52-Week High at $2.32

June 26, 2018 - By Joshua Cleveland

ContraFect Corporation (NASDAQ:CFRX) Corporate Logo

ContraFect Corporation (NASDAQ:CFRX) broke into $2.32 price per share also a one-year high. It was published on Jun, 26 by Barchart.com. The company has $170.89 million MC. $6.84 million more could be NASDAQ:CFRX valuation at $2.41 share price.

The stock increased 4.98% or $0.11 during the last trading session, reaching $2.32.ContraFect Corporation is uptrending after having risen 28.00% since June 26, 2017. CFRX has 162,715 volume or 41.28% up from normal. CFRX outperformed the S&P 500 by 15.43%.

On August, 8. Investors expect ContraFect Corporation (NASDAQ:CFRX) to report its quarterly earnings, RTT reports. EPS of $-0.10 is 33.33 % up from 2017’s $-0.15 EPS. Last quarter $-0.09 EPS was reported. Analysts sees 11.11 % negative EPS growth this quarter.

For more ContraFect Corporation (NASDAQ:CFRX) news posted recently go to: Benzinga.com, Benzinga.com, Globenewswire.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “40 Biggest Movers From Friday” posted on June 18, 2018, “44 Biggest Movers From Yesterday” on June 26, 2018, “ContraFect to Present at JMP Securities Life Sciences Conference” with a publish date: June 14, 2018, “A Possible Game Changer In The Antibiotics Field” and the last “ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram-Negative Pathogens at ASM …” with publication date: May 30, 2018.

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States.The firm is valued at $170.89 million. The Company’s lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of human influenza.Currently it has negative earnings. The firm has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.